@article{ATM19952,
author = {Biniam Kidane and Amir Ali and Joanne Sulman and Rebecca Wong and Jennifer J. Knox and Gail E. Darling},
title = {Health-related quality of life measure distinguishes between low and high clinical T stages in esophageal cancer},
journal = {Annals of Translational Medicine},
volume = {6},
number = {13},
year = {2018},
keywords = {},
abstract = {Background: Functional Assessment of Cancer Therapy-Esophagus (FACT-E) is a health-related quality of life (HRQOL) instrument validated in patients with esophageal cancer. It is made up of both a general component and an esophageal cancer subscale (ECS). Our objective was to explore the relationship between baseline FACT-E, ECS and clinically determined T-stage in patients with stage II–IV cancer of the gastroesophageal junction or thoracic esophagus.
Methods: Data from four prospective studies in Canadian academic hospitals were combined. These were consecutive and eligible patients treated between 1996 and 2014 with clinical stage II–IV cancer of the gastroesophageal junction or thoracic esophagus. All patients completed pre-treatment FACT-E. Parametric (ANOVA) and non-parametric (Kruskal-Wallis) analyses were performed.
Results: Of the 135 patients that were deemed eligible, the T-stage distribution determined clinically was: 10 (7.4%) T1, 33 (24.4%) T2, 79 (58.5%) T3 and 13 (9.6%) T4. Parametric analysis showed no significant association between FACT-E & T-stage, although there was a trend towards significance (P=0.08). Non-parametric analysis showed a significant association between FACT-E and T-stage (P=0.05). Post-hoc tests identified that the most significant differences in FACT-E scores were between T1 and T3 patients. Both parametric (P=0.002) and non-parametric (P=0.003) analyses showed an association between ECS & T-stage. Post-hoc analyses showed significant differences in ECS scores between T1 and higher T-stages (P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/19952}
}